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expenditures than hypertensive men. However, hypertensive men
had more utilization and expenditures attributed to hypertension
than hypertensive women. Hypertensive men and women with
similar health status and comorbid conditions did not have
similar utilization and expenditures regardless of their age,
income or insurance status. Thus, according to procedural
equity, hypertensive men and women were not being treated
equally.
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OBJECTIVE: To assess the inﬂuence of prescription drug cover-
age on physician recommendations for hypercholesterolemia
treatment, speciﬁcally comparing coverage types that employ
patient copayments and formulary restrictions with unrestricted
coverage. METHODS: Respondents from an ongoing web-based
survey of 2200 randomly-selected primary care physicians in
Florida, Massachusetts, North Carolina and Texas viewed a clini-
cal vignette of a patient with hypercholesterolemia and provided a
treatment recommendation. Insurance was randomly assigned as
commercial, Medicare Part D, Medicaid, or Medicare-Medicaid
dual eligible. Commercial insurance patients had no copayments
or formulary restrictions; other patients’ copayment and formu-
lary information depended on insurance type. We compared drug
choices across insurance groups using chi-square tests and root
mean squared deviations (RMSDs). RESULTS: Data from 229
respondents (1942 eligible, 11.8% response rate)were available at
time of submission; 53 respondents were randomized to patients
with commercial insurance, 59 to Part D, 59 to Medicaid, and 58
to dual eligible. Nearly all physicians (98%) recommended a
statin. Respondents were more likely to select a brand drug for
commercial insurance patients (66%) than for Medicare 22%),
Medicaid (37%), or dual eligible (29%, overall P < 0.001)
patients. The most-prescribed brand agent (atorvastatin) was
recommended more often and the most-prescribed generic agent
(simvastatin) was recommended less often for commercial insur-
ance patients (47%, 30% respectively) than for Medicare (8%,
61%), Medicaid (17%, 51%), and dual eligible (21%, 64%)
patients (overall P < 0.001). Drug choices for the Medicaid group
(RMSD 13.2) most closely approximated the commercial insur-
ance group’s distribution, followed by the dual-eligible (RMSD
15.8) and the Medicare (RMSD 17.8) groups. CONCLUSION:
These preliminary data indicate that physicians’ drug recommen-
dations for hypercholesterolemia treatment differ by patients’
insurance type. In particular, physicians recommended generic
drugsmore often than brand drugs for patientswith drug coverage
that uses copayments and formulary restrictions than for patients
with unrestricted drug coverage.
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OBJECTIVES: One recent analysis of brand to generic switching
patterns in a large, nationally representative pharmacy claims
database from January 2005 to June 2006 suggested that 3% of
patients taking atorvastatin were switched to simvastatin.
However, 38% of these switches were to less potent doses. This
analysis sought to assess the long-term impact of this switching
pattern in the US. METHODS: A Markov model simulated the
future cardiovascular health of Americans aged 35–74 years who
were initially free of cardiovascular disease (CVD), but who met
NCEP-ATPIII criteria for lipid-lowering treatment. Follow-up
occurred until age 75 years. Decision analysis was used to
compare the effects of prescribing all subjects atorvastatin versus
prescribing 97% atorvastatin and 3% simvastatin. Subjects were
proﬁled on participants of the 1999–2004 NHANES. The risks of
CVDand deathwere estimated from application of a Framingham
risk equation and derived from US mortality statistics, respec-
tively. The costs of CVD and statins were derived from adminis-
trative health care claims data. A uniform 3% annual discount
rate was applied. RESULTS: The analysis estimated a cohort of
24,037,997 Americans. If all were to be prescribed atorvastatin,
24.0% would be expected to suffer a cardiovascular event and
24.2% to die by age 75. If 3% were to be prescribed simvastatin
at the observed pattern, the equivalent ﬁgures would be 24.1%
and 24.3%, representing an excess of 2317 cardiovascular events
and 9987 deaths, respectively. There would be a net cost saving
associated with the switch, but at $42,400 per year of life lost and
$27,700 per QALY lost. CONCLUSIONS: In the US, many
patients are being inappropriately switched from atorvastatin to
generic simvastatin, which might lead to an increase in cardiovas-
cular events and overall mortality for little health-economic gain.
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OBJECTIVE: To estimate and compare lifetime (LT) medical
expenditure of hypertension among men and women of the
United States. METHODS: We estimated medical expenditures
with cross-sectional data and survival with prospective data, to
estimate lifetime expenditures from ages 20 to 85+. The 2001–
2004 Medical Expenditure Panel Survey (MEPS) were used to
estimate average annual medical expenditures. Total medical
expenditure was deﬁned as sum of inpatient stay, emergency
room visits, outpatient visits, ofﬁce based visits, and prescription
drugs expenditures. The 1986–2000 National Health Interview
Surveys (NHIS) were linked to mortality in the National Death
Index through 2002, to estimate survival with discrete time
hazard models. A discount rate of 3% was used to estimate the
LT medical expenditures. We controlled for hypertension status,
gender, age and race and ethnicity while estimating regression
models. In addition, interactions between hypertension and other
independent variables were controlled to differentiate different
levels of medical expenditures and mortality between hyperten-
sive and non-hypertensive individuals. Both total and hyperten-
sion attributable expenditures were estimated. RESULTS:
Expected total LT expenditure for individuals at age 20, was
$244,303 for hypertensive men and $259,499 for hypertensive
women. But the LT expenditure that could be attributed to
hypertension was $133,933 for men and $74,088 for women.
Therefore, hypertensive men had about 81% more attributable
LT expenditure relative to hypertensive women. Similarly, hyper-
tensive men of age 40 had about 88% more attributable LT
expenditure than hypertensive women, and hypertensive men of
age 60 had about 93% more attributable LT expenditure relative
to hypertensive women. CONCLUSION: Although hypertensive
women have more expected LT total expenditure than men,
hypertensive men had relatively more expected LT attributable
expenditure than women at different ages and the gap widened
with age.
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